Biomea Fusion Expects To Enroll First Participant In COVALENT-211 Phase IIb Trial In Q1 2026, Provides Business Updates For This Year

Biomea Fusion, Inc. ("Biomea," "Biomea Fusion" or "the Company") (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today outlined its execution priorities for 2026. The Company enters the year with strong operational momentum and a defined plan across its investigational metabolic programs, led by icovamenib, a potentially first-in-class investigational covalent menin inhibitor for diabetes, and BMF-650, an oral next-generation GLP-1 receptor agonist candidate in clinical development for obesity and metabolic disorders. Biomea remains focused on disciplined execution of its development strategy, advancing medicines designed to modify the underlying biology of diabetes and obesity with the goal of delivering durable clinical benefits.